Oppenheimer Reiterates $21.00 Price Target for Acorda Therapeutics (ACOR)
Oppenheimer set a $21.00 price objective on Acorda Therapeutics (NASDAQ:ACOR) in a research note issued to investors on Friday. The firm currently has a hold rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on ACOR. Goldman Sachs Group upgraded Acorda Therapeutics from a sell rating to a neutral rating in a report on Wednesday, February 7th. Piper Jaffray Companies upgraded Acorda Therapeutics from a neutral rating to an overweight rating and upped their target price for the company from $25.10 to $37.00 in a report on Thursday. ValuEngine cut Acorda Therapeutics from a hold rating to a sell rating in a report on Friday, February 9th. HC Wainwright set a $34.00 target price on Acorda Therapeutics and gave the company a buy rating in a report on Monday, November 20th. Finally, Jefferies Group upped their target price on Acorda Therapeutics from $22.00 to $25.00 and gave the company a hold rating in a report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Acorda Therapeutics currently has a consensus rating of Hold and an average price target of $22.51.
Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at $25.80 on Friday. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $33.00. The company has a market capitalization of $1,206.07, a P/E ratio of -5.33 and a beta of 1.63. The company has a quick ratio of 2.40, a current ratio of 3.07 and a debt-to-equity ratio of 0.64.
In other Acorda Therapeutics news, insider David Lawrence sold 31,000 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $27.58, for a total transaction of $854,980.00. Following the transaction, the insider now directly owns 5,275 shares in the company, valued at approximately $145,484.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Burkhard Blank sold 11,050 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the transaction, the insider now owns 33,150 shares in the company, valued at $680,569.50. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of ACOR. State Street Corp boosted its holdings in shares of Acorda Therapeutics by 52.4% during the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after buying an additional 851,290 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Acorda Therapeutics by 29.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock worth $46,745,000 after buying an additional 541,418 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Acorda Therapeutics by 65.2% during the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock worth $17,690,000 after buying an additional 354,304 shares in the last quarter. Bogle Investment Management L P DE bought a new position in shares of Acorda Therapeutics during the 4th quarter worth approximately $5,350,000. Finally, Millennium Management LLC acquired a new position in shares of Acorda Therapeutics during the fourth quarter worth approximately $4,264,000.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.